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Resistance of Streptococcus pneumoniae to
penicillin and other beta-lactams is increasing
worldwide (1-4). The major mechanism of
resistance involves the introduction of mutations
in genes encoding penicillin-binding proteins (5).
Selective pressure is thought to play an
important role, and use of beta-lactam antibiotics
has been implicated as a risk factor for infection
and colonization (6-14). Wide geographic spread
of resistant clones has been described (3,15).
However, the effect of geographic patterns of
antimicrobial-drug use on the emergence and
spread of resistance is not known.
We performed two previous surveillance
studies of S. pneumoniae isolated at medical
centers in the United States, one in 1994-95 (16),
the other in 1997-98 (17). We report the
relationship between antimicrobial-drug use in
the geographic areas surrounding these medical
centers and the change in penicillin resistance of
S. pneumoniae over a 3-year period.
The Study
Multicenter national surveillance of
S. pneumoniae was performed from November
1994 to April 1995 (16) and again from November
1997 to April 1998 (17). All isolates during these
two surveillance studies were recovered from
consecutive nonhospitalized patients from either
the lower respiratory tract or a sterile site (blood
or cerebrospinal fluid). Briefly, isolates were
transported from study centers to a central
laboratory, where they were confirmed as
S. pneumoniae by conventional identification
methods (16). Susceptibility testing was performed
by the reference broth microdilution method
recommended by the National Committee for
Clinical Laboratory Standards (NCCLS) (18).
Susceptibility was determined by using the
established NCCLS breakpoints (19). For
penicillin, breakpoints of 0.1 to 1.0 µg/mL for
intermediate and >2 µg/mL for resistant were
used; for this analysis, both intermediate and
resistant categories were considered resistant.
Twenty-four medical centers were surveyed
during both study periods. For 23 of these
centers, data for outpatient antimicrobial-drug
use were obtained for the surrounding metropoli-
tan statistical area. These data were expressed in
terms of number of prescriptions written per
100,000 population per month during the 48-
month period that included the two surveillance
studies (20). This period (May 1994 through April
1998) included four consecutive respiratory virus
seasons. We divided the 23 medical centers into
high-, intermediate-, and low-use centers for
each antimicrobial-drug class. With the change
in penicillin resistance as the dependent variable
of interest, we used one-way ANOVA to compare
mean change in resistance to penicillin between
high-, intermediate-, and low-use centers. We
then analyzed covariance models to evaluate
the relationship between antimicrobial-drug
use categories and changes in penicillin
resistance. Alpha was set at 0.05, and all
p-values were two-tailed.
We compiled the penicillin and erythromycin
susceptibility test results for S. pneumoniae
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Table 1. Change in resistancea among Streptococcus pneumoniae isolates at 23 U.S. medical centers, 1994-95
and 1997-98
   No. of  Study Change Penicillin Change
Medical center isolates period Erythromycin (%) I + Rb    (%)
Seattle, WA      37 1994-95   5.4 35.1
     50 1997-98 30.0 24.6 38.0    2.9
Denver, CO      62 1994-95   3.2 14.5
     26 1997-98   7.7   4.5 15.4    0.9
Phoenix, AZ      57 1994-95 12.3 40.4
     54 1997-98 35.2 22.9 40.7    0.3
Houston, TX      63 1994-95 22.2 25.4
     48 1997-98 43.8 21.6 64.6  39.2
Dallas, TX      58 1994-95   6.9 22.4
     36 1997-98 27.8 20.9 30.5    8.1
Rochester, MN      35 1994-95   8.6 14.2
     48 1997-98 20.8 12.2 22.9    8.7
Milwaukee, WI      65 1994-95 18.5 33.8
     55 1997-98 10.9  -7.6 20.0 -13.8
Evanston, IL      49 1994-95   8.2 14.3
     35 1997-98 14.3   6.1 14.3    0.0
Chicago, IL      41 1994-95 17.1 34.1
     41 1997-98 19.5   2.4 19.5 -14.6
Indianapolis, IN      63 1994-95   7.9 20.7
     55 1997-98 18.2 10.3 25.5    4.8
St. Louis, MO      57 1994-95   8.9 24.6
     55 1997-98 12.7   3.8 29.1    4.5
Detroit, MI      63 1994-95   6.3 19.0
     60 1997-98 10.0   3.7 30.0  11.9
Cleveland, OH      42 1994-95 11.9 19.0
     60 1997-98 20.0   8.1 23.2    4.2
Philadelphia, PA      47 1994-95   2.1   2.1
     42 1997-98 11.9   9.8 21.4  19.3
Syracuse, NY      23 1994-95   8.7   8.7
     50 1997-98   8.0   -0.7 20.0  11.3
Rochester, NY      58 1994-95   6.9 10.4
     50 1997-98 12.0   5.1 20.0    9.6
New York, NY      64 1994-95   4.7 12.6
     53 1997-98   3.8  -0.9 20.8    8.2
Hartford, CT      61 1994-95   3.3   8.2
     51 1997-98   7.8   4.5 27.4  19.2
Washington, DC      60 1994-95 13.3 23.3
     28 1997-98 28.6 15.3 35.7  12.4
Chapel Hill, NC      60 1994-95 10.0 31.7
     49 1997-98 38.8 28.8 57.1  25.4
Decatur, GA      61 1994-95 23.0 36.1
     52 1997-98 26.9   3.9 44.2    8.1
Mobile, AL      68 1994-95 16.2 20.6
     58 1997-98 37.9 21.7 41.3  20.7
Miami, FL      17 1994-95   5.9 52.9
     27 1997-98 29.6 23.7 51.8   -1.1
TOTAL 1,211 1994-95 10.2 22.2
1,083 1997-98 20.6 10.4 31.1    8.9
aIncludes both intermediate- and high-level resistance to penicillin and erythromycin.
bI + R = both intermediate and fully resistant.
isolates collected in 1994-95 and 1997-98 from all
23 centers (Table 1). Overall, penicillin nonsus-
ceptibility (MIC > 0.1 µg/mL) increased by 8.9%.
In 1994-95, 269 (22.2%) of the 1,211 S. pneumoniae
isolates were intermediate or fully resistant to
penicillin, while in 1997-98, 337 (31.1%) of the
1,083 isolates were in these categories. When the
change in percent penicillin susceptibility at each554 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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Table 3. Mean increase in percent penicillin
resistancea of Streptococcus pneumoniae by categoryb
of antimicrobial-drug use
Inter-
Class High mediate Low p-valuec
Beta-lactams 13.3   8.8   2.8 0.20
Quinolones 13.0   6.3   5.3 0.39
Macrolides   4.0 12.4   8.9 0.39
Tetracyclines   5.3   7.7 11.8 0.56
All classes 13.3   3.3   7.6 0.27
aIncludes both intermediate- (MIC 0.12-1 µg/mL) and high-
level (MIC >2 µg/mL) resistance to penicillin.
bEach center was categorized by total number of outpatient
prescriptions for the antimicrobial class per 100,000
population per month in the surrounding metropolitan
statistical area.
cOne-way ANOVA p-value, two-tailed.
Table 2. Prescriptions for antibiotics at medical centers
with high, intermediate, and low antimicrobial-drug usea
Class/tertile Mean  Median Range SD
Beta-lactams
  High 1,640 1,620 1,186-2,557 411
  Intermediate 1,027 1,040    948-1,136   69
  Low    859    870    777-917   51
Macrolides
  High    929    865    800-1,286 166
  Intermediate    738    722    687-787   35
  Low    609    623    528-673   52
Quinolones
  High    282    258    222-424   63
  Intermediate    197    200    177-216   16
  Low    143    146      91-170   27
Tetracyclines
  High      77      75      61-100   15
  Intermediate      56      58      50-59     3
  Low      33      34      25-45     7
aAll values are expressed in units of mean number of
prescriptions per 100,000 population per month during the
period between the two surveillance studies (May 1994-April
1998).
Table 4. Analysis of covariance model, with change in
penicillin resistance at each of the 23 medical centers as
the dependent variable
Type III Parameter
sums of estimate
Source squares (B) F p-value
Overall model    990a 4.8 0.02
Intercept      56  4.5 0.5 0.47
β -lactam use    893  8.6 8.7 0.008
Macrolide use    553 -6.7 5.4 0.031
Error 2,054
Total 4,616
Corrected total 3,045
aR2 = 0.325.
center was considered, the overall mean increase
in penicillin resistance was 8.3% (-14.6% to
39.2%) among the 23 centers that participated in
both surveys (Table 1).
Antimicrobial-drug use data for beta-lactams,
tetracyclines, quinolones, and macrolides were
calculated for the high-, intermediate-, and low-
use tertiles in our analysis (Table 2). The mean
increase in penicillin resistance was compared
among high-, intermediate-, and low-use centers
for the major antibiotic classes (Table 3). The
beta-lactams were most strongly associated with
an increase in penicillin resistance (2.8%, 8.8%,
and 13.3% increases in low-, intermediate-, and
high-use tertiles, respectively, p=0.20).
Univariate analysis of covariance was
performed, with change in penicillin resistance
as the dependent variable and the antimicrobial-
drug use category for each antimicrobial-drug
class as independent variables. When all
classes for which data were available (beta-
lactams, tetracyclines, macrolides, and
quinolones) were entered into a model, only the
macrolides and beta-lactams were statistically
significant (p< 0.1) as explanatory variables and
were therefore included in the final model (Table
4). Higher beta-lactam use was strongly
associated with increased resistance to penicillin
(F=8.7, p=0.008). Conversely, higher macrolide
use was associated with decreased resistance
to penicillin (F=5.4, p=0.031). The overall
model explained a significant amount of the
variance in penicillin resistance at these 23
centers (F=4.8, p=0.02).
A separate analysis showed no significant
association between beta-lactam, macrolide,
quinolone, or tetracycline use and change in the
percentage of erythromycin resistance. However,
an overall increase in erythromycin resistance
was observed (Table 1).
Conclusions
Numerous studies have associated antimi-
crobial-drug use patterns in hospitals with the
emergence of resistance among nosocomial
pathogens (21-25). However, S. pneumoniae is
usually acquired outside the hospital environ-
ment; therefore, establishing a relationship
between antimicrobial-drug use and resistance
requires outpatient data, as well as susceptibility
test results. A large-scale study of this type is
costly and difficult to perform in the United
States, given the problems inherent in collecting
accurate data from multiple outpatient settings.
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planning of such a study, we used data collected
for other purposes to explore the relationship
between outpatient antimicrobial-drug use and
resistance among S. pneumoniae isolates.
We found an association between the
outpatient use of beta-lactam antimicrobial
drugs in metropolitan areas and changes in the
penicillin susceptibility of S. pneumoniae isolates
sampled from tertiary care centers in those
metropolitan areas. Determining whether this
association is spurious or causal requires further
investigation, given the limitations of our study
design. Since information about each patient’s
previous antimicrobial-drug use was not avail-
able, we were unable to make a direct connection
between patient use and risk for resistance.
Furthermore, since antimicrobial-drug use data
are presented as the total number of prescrip-
tions per month in the population, the data may
not accurately reflect use. Patient compliance,
dosage prescribed, and duration of antibiotic use
may differ from region to region. In addition, the
data are for large populations, and the
S. pneumoniae isolates represent a small sample
from one study center in each metropolitan
statistical area. These samples may not
accurately reflect the true prevalence of
resistance in the study population. For this
reason, we grouped the study centers into tertiles
on the basis of use, to decrease the impact of a
small number of resistant isolates at a single
study center. Finally, this analysis was retro-
spective. These surveillance surveys were not
designed to evaluate the association between
antimicrobial-drug use and changing resistance
patterns among S. pneumoniae.
However, the use of antimicrobial agents in a
population would be expected to contribute to the
emergence and spread of resistance within that
population, and our data support this hypothesis
for beta-lactam use and penicillin resistance. The
fact that beta-lactam use was associated with
increased penicillin, but not erythromycin,
resistance among pneumococcal isolates in our
study suggests a specific association. Further-
more, this positive association with penicillin
resistance was not seen for antimicrobial-drug
classes other than the beta-lactams; neither was
resistance associated with the total number of
antimicrobial-drug prescriptions.
Erythromycin resistance also increased
during our study. The lack of a strong association
between use and erythromycin resistance may
reflect the fact that beta-lactams were the most
commonly prescribed in the metropolitan
statistical areas we studied, and the impact of
these drugs was therefore greater and easier to
detect. In addition, a relationship between
resistance to penicillin and resistance to virtually
all other oral antimicrobial-drug classes has been
described (2,16-17), making colinearity a poten-
tial problem in evaluating the impact of specific
classes on resistance to a single antimicrobial
agent or class. If the relationship between
penicillin resistance and resistance to other
antimicrobial-drug classes is due to the clonal
spread of already multidrug-resistant strains
(rather than emergence of resistance under
antimicrobial pressure), the impact of a specific
class of agent on the spread of a specific
resistance in S. pneumoniae might vary by
region, depending on the coresistance pattern of
the predominant PRSP clones in that area.
Other investigators have reported an asso-
ciation between prescriptions for outpatients and
rates of resistance in Western Europe (26),
Hungary (27), and Iceland (28). In these studies,
lower use of antimicrobial drugs in general and
beta-lactams in particular is associated with
lower rates of isolation of resistant strains. Our
study supports this association and underscores
the importance of implementing measures to
decrease the inappropriate use of antibiotics in
the outpatient setting (29).
Despite several limitations, our data support
the hypothesis generated in previous studies that
outpatient antimicrobial-drug use plays an
important role in the development and spread of
resistance. In future epidemiologic studies,
antimicrobial-drug use should be carefully
matched with resistance in well-defined popula-
tions and should include prospective evaluation
of interventions to reduce the use of certain
classes of antimicrobial agents for outpatients.
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